Seeking Alpha

AstraZeneca's (AZN) blockbuster cholesterol drug Crestor failed to beat Pfizer's (PFE) Lipitor...

AstraZeneca's (AZN) blockbuster cholesterol drug Crestor failed to beat Pfizer's (PFE) Lipitor in a head-to-head study. The result is likely to cap any benefits AZN might have gained from when Lipitor loses its patent in November and cheap generics hit the market. Shares -3.3% in London. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|